Gilead Sciences Inc. shares had their biggest intraday gain since 2012 on Friday after a report that a group of patients being treated in Chicago were “seeing rapid recoveries in fever and respiratory symptoms.”
The report, from the medical news publication Stat, cited a video made by a researcher at the University of Chicago who is helping conduct a trial of Gilead’s drug remdesivir. The researcher, infectious disease professor Kathleen Mullane, said that most patients had been discharged from the hospital and only two had died, according to Stat.
